Approved Myeloma Drug in Limbo After Negative ODAC Review

(MedPage Today) -- The FDA's Oncologic Drugs Advisory Committee (ODAC) may have dealt a decisive blow to the dangling accelerated approval of melphalan flufenamide (Pepaxto) for multiple myeloma. By a decisive 14-2 margin, ODAC voted on Thursday...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news